mRNA editing of the Alzheimer's risk gene APOE
- 1University of Edinburgh
Abstract
Variants in the human APOE gene govern the risk of Alzheimer's disease and other disorders. Three major APOE variants in humans reflect C to T replacements at two positions in a single exon: an upstream variant (AE4 site) that differs between the ancestral APOE epsilon 4 allele (APOE4) (C) and human-specific APOE2/E3 (T), and a downstream variant (AE2 site) that differentiates APOE3/E4 (C) from APOE2 (T). It has long been assumed that APOE allelotypes are genomically encoded, but here we report that multiple individuals express brain APOE C or U/T variant transcripts that differ from genomically templated versions. We demonstrate up to 10% C to U, or U to C nucleotide replacement at AE4 and AE2, but not at other sites, and with no corresponding changes in genomic DNA. Single-cell transcriptomic datasets from brain microglia revealed sporadic (up to ~8%) C to U replacement at AE2. We found 0.4 to 1.6% of brain transcripts in human APOE knock-in mice harbor selective C to U changes at either AE4 or AE2 sites. Transfection of HepG2 or Huh7 cells with either mouse or human APOBEC1 led to efficient (>90%) C to U editing of APOE4 mRNA at the AE4 but not AE2 site, with lower (<10%) C to T editing of genomic DNA at the AE4 site by mouse, but not human, APOBEC1. Furthermore, interrogation of proteomic datasets revealed up to 4% of non-genomically encoded APOE peptides in human plasma, indicating that the edited APOE transcripts are functional in vivo. These data suggest that APOE mRNA is subject to RNA editing that interconverts the different allelic forms of APOE.
Related
- Proteomic signatures of the APOE ε4 and APOE ε2 genetic variants and Alzheimer’s disease
- Single-cell transcriptomic atlas of Alzheimer's disease middle temporal gyrus reveals region, cell type, and sex specificity of gene expression with novel genetic risk for MERTK in female
- Cross‐tissue immune profiling of APOE ε4 reveals early dysregulation in Alzheimer's disease
- The Alzheimer's disease risk gene ABCA7 regulates microglial lysosomal and lipid homeostasis and promotes phagocytosis to maintain neuronal health
- Engineered mRNA-packaging virus-like particles enable efficient and precise mitochondrial base editing in vitro and in vivo
BibTeX
@misc{blanc2026mrna,
title = {{mRNA editing of the Alzheimer's risk gene APOE}},
author = {V. Blanc and S. J. Griffiths and J. Haas and N. Davidson and R. Lathe},
howpublished = {bioRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.03.749263},
url = {https://www.biorxiv.org/content/10.64898/2026.09.03.749263v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - mRNA editing of the Alzheimer's risk gene APOE
AU - V. Blanc
AU - S. J. Griffiths
AU - J. Haas
AU - N. Davidson
AU - R. Lathe
PY - 2026
DA - 2026/09/03
PB - bioRxiv
DO - 10.64898/2026.09.03.749263
UR - https://www.biorxiv.org/content/10.64898/2026.09.03.749263v1
AB - Variants in the human APOE gene govern the risk of Alzheimer's disease and other disorders. Three major APOE variants in humans reflect C to T replacements at two positions in a single exon: an upstream variant (AE4 site) that differs between the ancestral APOE epsilon 4 allele (APOE4) (C) and human-specific APOE2/E3 (T), and a downstream variant (AE2 site) that differentiates APOE3/E4 (C) from APOE2 (T). It has long been assumed that APOE allelotypes are genomically encoded, but here we report that multiple individuals express brain APOE C or U/T variant transcripts that differ from genomically templated versions. We demonstrate up to 10% C to U, or U to C nucleotide replacement at AE4 and AE2, but not at other sites, and with no corresponding changes in genomic DNA. Single-cell transcriptomic datasets from brain microglia revealed sporadic (up to ~8%) C to U replacement at AE2. We found 0.4 to 1.6% of brain transcripts in human APOE knock-in mice harbor selective C to U changes at either AE4 or AE2 sites. Transfection of HepG2 or Huh7 cells with either mouse or human APOBEC1 led to efficient (>90%) C to U editing of APOE4 mRNA at the AE4 but not AE2 site, with lower (<10%) C to T editing of genomic DNA at the AE4 site by mouse, but not human, APOBEC1. Furthermore, interrogation of proteomic datasets revealed up to 4% of non-genomically encoded APOE peptides in human plasma, indicating that the edited APOE transcripts are functional in vivo. These data suggest that APOE mRNA is subject to RNA editing that interconverts the different allelic forms of APOE.
ER -